Search

Your search keyword '"Oksanen, Minna"' showing total 7 results
Start Over Author "Oksanen, Minna" Publisher wiley
7 results on '"Oksanen, Minna"'

1. NF‐E2‐related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin‐1 mutated Alzheimer's disease astrocytes

Author

Oksanen, Minna, primary, Hyötyläinen, Ida, additional, Trontti, Kalevi, additional, Rolova, Taisia, additional, Wojciechowski, Sara, additional, Koskuvi, Marja, additional, Viitanen, Matti, additional, Levonen, Anna‐Liisa, additional, Hovatta, Iiris, additional, Roybon, Laurent, additional, Lehtonen, Šárka, additional, Kanninen, Katja M., additional, Hämäläinen, Riikka H., additional, and Koistinaho, Jari, additional

Published
2019
Full Text
View/download PDF

2. PPARβ/δ‐agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes

Author

Konttinen, Henna, primary, Gureviciene, Irina, additional, Oksanen, Minna, additional, Grubman, Alexandra, additional, Loppi, Sanna, additional, Huuskonen, Mikko T., additional, Korhonen, Paula, additional, Lampinen, Riikka, additional, Keuters, Meike, additional, Belaya, Irina, additional, Tanila, Heikki, additional, Kanninen, Katja M., additional, Goldsteins, Gundars, additional, Landreth, Gary, additional, Koistinaho, Jari, additional, and Malm, Tarja, additional

Published
2018
Full Text
View/download PDF

3. [P3-170]: HUMAN IPSC-DERIVED ALZHEIMER's DISEASE ASTROCYTES RECAPITULATE DISEASE-RELATED PHENOTYPES

Author

Oksanen, Minna, primary, Petersen, Andrew J., additional, Puttonen, Katja, additional, Hämäläinen, Riikka H., additional, Lehtonen, Šárka, additional, Leskelä, Stina, additional, Shakirzyanova, Anastasia, additional, Naumenko, Nikolay, additional, Viitanen, Matti, additional, Rinne, Juha O., additional, Kanninen, Katja, additional, Haapasalo, Annakaisa, additional, Tavi, Pasi, additional, Zhang, Su-Chun, additional, and Koistinaho, Jari, additional

Published
2017
Full Text
View/download PDF

4. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans

Author

Bramante, Simona, primary, Kaufmann, Johanna K., additional, Veckman, Ville, additional, Liikanen, Ilkka, additional, Nettelbeck, Dirk M., additional, Hemminki, Otto, additional, Vassilev, Lotta, additional, Cerullo, Vincenzo, additional, Oksanen, Minna, additional, Heiskanen, Raita, additional, Joensuu, Timo, additional, Kanerva, Anna, additional, Pesonen, Sari, additional, Matikainen, Sampsa, additional, Vähä-Koskela, Markus, additional, Koski, Anniina, additional, and Hemminki, Akseli, additional

Published
2015
Full Text
View/download PDF

5. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

Author

Pesonen, Sari, primary, Diaconu, Iulia, additional, Cerullo, Vincenzo, additional, Escutenaire, Sophie, additional, Raki, Mari, additional, Kangasniemi, Lotta, additional, Nokisalmi, Petri, additional, Dotti, Gianpietro, additional, Guse, Kilian, additional, Laasonen, Leena, additional, Partanen, Kaarina, additional, Karli, Eerika, additional, Haavisto, Elina, additional, Oksanen, Minna, additional, Karioja-Kallio, Aila, additional, Hannuksela, Päivi, additional, Holm, Sirkka-Liisa, additional, Kauppinen, Satu, additional, Joensuu, Timo, additional, Kanerva, Anna, additional, and Hemminki, Akseli, additional

Published
2011
Full Text
View/download PDF

7. Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

Author

Pentikäinen M, Simonen P, Leskelä P, Harju T, Jääskeläinen P, Asseburg C, Oksanen M, Soini E, Wennerström C, Puhakka A, and Kahlos K

Abstract

Treatment patterns of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland are unknown. Guidelines now recommend early escalation of treatment for PAH. We evaluated how well Finnish practice follows guidelines, and how treatment initiations and outcomes are related. The pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Finland cohort includes all PAH and CTEPH patients diagnosed between 2008 and 2020 in all Finnish university hospitals. Drug therapy was analysed in patients with medical/procedural history available, and changes in the 4-tier comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA) 2.0 risk score were evaluated. PAH patients ( n  = 268) were initially treated with monotherapy (52%) or double therapy (24%). After year 2015, double therapy use increased to 39%. PAH treatment at 1 year after diagnosis included phosphodiesterase 5 inhibitors (71%), endothelin-receptor antagonist (48%), prostacyclin analogue (7%), calcium channel blocker (12%) and selexipag (1%). 35% achieved low risk at 1 year, increasing to 44% for patients diagnosed after 2015. Those remaining at intermediate-high (IH) or high risk (H) (28%) were not treated less aggressively than others but were older, had more comorbidities, and often history of smoking. CTEPH patients ( n  = 189) were treated with pulmonary endarterectomy (PEA) (27%), balloon pulmonary angioplasty (BPA) (11%) and medical therapy only (41%) within 1 year from diagnosis. 45% achieved low risk at 1 year. We present additional results on treatment of IH and H patients, patient characteristics preceding death, and treatment persistence. We found less treatment of PAH patients with double or triple therapies and of CTEPH patients with PEA and BPA than expected but with good results. Patients not reaching low or intermediate COMPERA 2.0 were old and had comorbidities., Competing Interests: Financial relationships in the last 24 months. Markku Pentikäinen: AOP Health, AstraZeneca, Bayer, Boehringer‐Ingelheim, GE Healthcare, Janssen, MSD, Orion Pharma. Piia Simonen: Janssen. Pauliina Leskelä: Abbott, Janssen, Medtronic. Terttu Harju: Janssen, Nordic Infucare. Pertti Jääskeläinen: Janssen. Christina Wennerström: Janssen. Airi Puhakka: Bittium, Idorsia, Janssen, Johnson and Johnson. The remaining authors declare no conflicts of interest., (© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results